Please login to the form below
CAR-T therapies
This page shows the latest CAR-T therapies news and features for those working in and with pharma, biotech and healthcare.
MaxCyte gets green light for solid tumour cell therapy
The current generation of CAR-T therapies – namely Novartis’Kymriah (tisagenlecleucel) and Gilead/Kite’s Yescarta (axicabtagene ciloleucel) – use engineered T cells harvested from blood, which have to be expanded in ... Difficulties in getting to
Latest news
-
Sanofi’s rare blood disorder drug Cablivi set for European approval
The EMA’s Committee for Medicinal Products for Human Use (CHMP) gave its blessing to Cablivi (caplacizumab) at its monthly meeting last week, along with three other rare disease therapies, two ... CAR-T therapies and the usual clutch of new drugs and
-
Drugs for rare diseases will help propel pharma sales to $1.2trn by 2024; report
Gene and cell therapies will also be a growth driver as prescription drug sales grow at more than 6% a year to reach $1.2trn in 2024 – a six-fold increase ... Multiple new cell and gene therapy approvals are expected in the wake of the launches of
-
Bluebird and Celgene BCMA CAR-T kicks off ASCO
Bluebird and Celgene BCMA CAR-T kicks off ASCO. Will be reporting updated phase I trial data for bb2121in patients with bone marrow cancer. ... well as preclinical data in the much tougher challenge of using CAR-T therapies to tackle solid tumours.
-
NHS chief pledges CAR-T support, but asks for pricing restraint
NHS chief pledges CAR-T support, but asks for pricing restraint. The plea comes as the EMA reviews two CAR-T therapies. ... NHS England chief executive Simon Stevens has said that new CAR-T therapies for cancer could become available to NHS patients this
-
Gilead signs $3bn-plus gene-editing deal with Sangamo
The company seems determined to stay in the forefront of the pharma industry’s push into cell therapies, with the latest deal coming shortly after it acquired CAR-T specialist Kite ... to ten off-the-shelf (allogeneic) as well as autologous CAR-T
More from news
Approximately 3 fully matching, plus 28 partially matching documents found.
Latest Intelligence
-
The good, the bad and the ugly
The company hopes its $12bn acquisition of Kite Pharma (August 2017) will help it steal a march on the lucrative CAR-T market through its treatment for advanced lymphoma. ... It will also be interesting to see how gene therapies and cell-based therapies,
-
Cell and gene therapies: on course for commercial success?
The data for the research was derived from published data on CAR-T pipeline therapies, but was not related to any particular product. ... transplant. As a result, there may be no existing mechanism for these centres to obtain funding for any additional,
-
Deal Watch November 2016
were thought to be a result of the chemotherapy regimen used to prepare the patients before administering the CAR T cell therapy. ... their own CAR T cell therapies - so CAR T cell therapy seems to be still alive and doing well.
-
Deal Watch September 2016
The lead programme EM801 is a T cell bispecific antibody targeting B-cell maturation antigen (BCMA), which s considered to be complementary to Bluebird bio's CAR T cell therapies targeting ... 800. Arrowhead / Amgen. Licences. 2 agreements to develop and
-
Deal Watch April 2016
Rova-T showed a 44% overall response rate in DLL-expressing small cell lung cancer (SCLC) patients who had failed one or more standard therapies. ... 61. Celgene (US). Juno (US). Option exercised to extend territory. Phase II CD19-based CAR T therapies
More from intelligence
Approximately 0 fully matching, plus 10 partially matching documents found.
Latest from PMHub
-
Training the next generation of biotech leaders
In this year alone, the FDA has taken the groundbreaking step of approving two CAR-T therapies. ... From dream to reality. The approval of two CAR-T therapies this year illustrates how cell and gene therapies are turning from scientific dream to reality,
-
Addressing the biggest challenges for rare disease communities
It is common that primary care physicians either do not recognise specific symptoms or don’ t make the link between common symptoms and a rare disease. ... And just last year, we saw landmark breakthroughs in advanced genetic therapies, such as viral
-
Addressing the biggest challenges for rare disease communities
It is common that primary care physicians either do not recognise specific symptoms or don’ t make the link between common symptoms and a rare disease. ... And just last year, we saw landmark breakthroughs in advanced genetic therapies, such as viral
More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.
Featured jobs
- Account Director, Consumer Healthcare PR, Global PR agency
-
£50, 000 – £58, 000
- Head of Market Access - International - Based Cambridge
-
Excellent Basic, Bonus and Flex Benefits
- Home based, Principal Medical Writer, Medical Communications
-
Excellent package
- Account Manager, Medical Communications and Marketing
-
£30, 000 – £40, 000 benefits and bonus
- Strategic Planner, Healthcare Advertising
-
£47, 000 – £53, 000
- Home based, Senior Medical Writer, Medical Communications
-
Excellent package
-
Healthcare PR Director
-
£100, 000 – £120, 000 benefits
-
Client Services Director - Med Comms
-
Great salary and bebefits
- Home based, Chief Medical Writer, Medical Communications
-
Excellent package
- Business Unit Head, Medical Communications, London
-
Excellent package
- Principal Medical Writer / Editorial Director – Medical Communic...
-
£60, 000 - £80, 000
- Account Director, Medical Communications
-
C£50 – 65, 000 benefits and bonus
-
Account Manager
-
£40, 000 - £45, 000 benefits
- Senior Medical Writer, Healthcare Advertising Agency
-
£45, 000 – £50, 000
-
Senior Account Manager
-
Competitive salary commensurate with experience
- Home based, Editorial Team Leader, Medical Communications
-
Excellent package
Subscribe to our email news alerts
- Communiqué Awards 2018: Photo Gallery - Communiqué Awards 2016
- GSK sells eczema and psoriasis drug to Dermavant for £250m
- Moving annual total (MAT)
- Roche keeps Venclexta train rolling with new leukaemia filing
- NHS England says yes to Roche's Hemlibra
- Daily Brief: Trump arrives in London, NICE says no to Darzalex, Pfizer backs down on prices
- Daily brief: Novartis spends big on ezcema, Kite invests, another gene therapy IPO
- Ashfield Meetings & Events welcomes largest intake of students in seventh year of undergraduate placement scheme
- AstraZeneca joins Merck in Brexit stockpiling effort
- Vyriad inks immunotherapy alliance with Merck/Pfizer
- Huntsworth buys Giant Creative Strategy
- Daily Brief: success for Pfizer and Lilly arthritis drug, Darzalex soars, IMI launches Accelerator
PMHub
mXm Medical Communications
mXm Medical Communications meets the needs of pharmaceutical marketers and medics who require a highly experienced, bespoke service from their...
Latest intelligence
- Developing advocacy in the pharmaceutical industry.
- The importance of advocacy programmes...
- GDPR and events. What does the pharma industry need to know?
- Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
- Digital trends in B2B sales - how far behind is Pharma?
- The modern approach to B2B sales is data-driven, and enabled by digital tools....
Quick links
Infographics
